Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Common Equity (2016 - 2025)

Agios Pharmaceuticals' Common Equity history spans 14 years, with the latest figure at $1.2 billion for Q4 2025.

  • For Q4 2025, Common Equity fell 22.57% year-over-year to $1.2 billion; the TTM value through Dec 2025 reached $1.2 billion, down 22.57%, while the annual FY2025 figure was $1.2 billion, 22.57% down from the prior year.
  • Common Equity reached $1.2 billion in Q4 2025 per AGIO's latest filing, down from $1.3 billion in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $2.3 billion in Q1 2021 to a low of $660.5 million in Q2 2024.
  • Average Common Equity over 5 years is $1.2 billion, with a median of $1.2 billion recorded in 2022.
  • Peak YoY movement for Common Equity: skyrocketed 267.29% in 2021, then tumbled 47.43% in 2022.
  • A 5-year view of Common Equity shows it stood at $1.3 billion in 2021, then fell by 14.8% to $1.1 billion in 2022, then dropped by 26.33% to $811.0 million in 2023, then soared by 90.0% to $1.5 billion in 2024, then dropped by 22.57% to $1.2 billion in 2025.
  • Per Business Quant, the three most recent readings for AGIO's Common Equity are $1.2 billion (Q4 2025), $1.3 billion (Q3 2025), and $1.4 billion (Q2 2025).